Description
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price.
- Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical and POC diagnostic companies
- Rx to OTC Switches After a short respite, the Rx to OTC switch is back as a revenue enhancement strategy. Kalorama Information details markets for Rx to OTC across various therapeutic categories.
- Prescribing Pharmacists Many states will allow pharmacists to prescribe soon. Some already do in limited circumstances. In this report, a new decision maker revealed, and the impact of the trend is quantified.
- Drug Pricing: Preparing for the Coming Generic Onslaught Strategies for companies deciding on the most important marketing decision in the 2008.
- Growing Out of Pocket Healthcare Market Kalorama identifies and calculates the market for pharmaceuticals and other healthcare paid for by recipients themselves.
This bundle represents the complete content of the 5 market research reports. This single package represents crucial knowledge for decision makers in the pharmaceutical industry today.
Table of Contents
Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught
- Drug Pricing and Reimbursement: Strategic Overview
- Factors affecting Pharmaceutical Expenditur
- Key Issues and Challenges
- Regional Pricing Differences
- Reasons for Conducting the Study
- Drug Pricing and Reimbursement: Strategic Perspectives
- 2.2. Global healthcare costs and their Impact on GDP
- 2.3. Drug Costs and Affordability
- 2.3.1. Price Variability across countries
- 2.4. Factors contributing to Drug Expenditures
- 2.5. Pharmaceutical Pricing and Ethics
- 2.5.1. Differential Pricing
- 2.5.2. HIV/AIDS Pricing & Ethics
- 3.2. Pricing Strategies: Goals
- 3.2.2. Defending Market share
- 3.2.4. Enhancing Brand Loyalty
- 3.2.6. Capacity Utilization
- 3.3. Pricing Decisions: Types
- 3.3.1. Traditional Pricing
- 3.4. Role of Pricing Function in Price setting
- 3.5. Pricing and Pharmacoeconomics
- 3.7. Pricing in the Product Development Process
- 3.7.2. The First Price Estimate
- 3.7.3. Improving Pricing in the Product Development Process
- Current Pricing and Reimbursement Trends in the USA
- 4.1.U.S. Healthcare Expenditures4.1.1. National Prescription Drug Expenditures
- 4.1.2 Pharmaceutical Costs
- 4.1.2.3. Factors for rise in pharmaceutical costs
- 4.1.3. Future trends in Pharmaceutical Costs
- 4.1.3.2. Increased Generic Penetration4.1.3.2. Rising Consumerism
- 4.1.3.4. Shifting Payor Mix
- 4.1.3.5. Cost Containment and the Formulary
- 4.1.3.6. Basis of price determination
- 4.2. Pricing mechanism in USA
- 4.3.1 Impact of Supply Chain on Price
- 4.3.2. Supply chain and price differentials
- 4.4. Key Pricing measures
- a) Average Manufacturer’s Price (AMP)
- b) Average Sales Price (ASP)
- c) Average Wholesale Price (AWP)
- d) Estimated Acquisition Cost (EAC)
- e) Federal Supply Schedule.
- f) Federal Upper Limit (FUL)
- g) Maximum Allowable Cost (MAC)
- h) Wholesale Acquisition Cost (WAC)
- 4.5. Drug Pricing Litigations
- 4.7. Pricing and customer segments
- 4.7.2 Pharmacy Benefit Managers
- Cost containment Strategies
- PBMs’ Negotiated Payments to Pharmacies
- PBMs’ Payments to Pharmacies
- 4.7.3. Mail-Order Pharmacies
- 4.7.5. Government Markets
- 4.7.5.1. Federal Supply Schedule
- 4.7.5.2. 340B Drug Discount Program
- c) Part C (Medicare Advantage)
- 2008 Changes in Medicare Part D Payments
- Calculation of the Low-Income Benchmark Premium Amounts
- Annual Updates to Medicare Part D Benefit Parameters
- 4.7.6. Third party payors
- Managed care business structure
- Healthcare maintenance organizations (HMO)
- Preferred provider organizations (PPO)
- MCOs and Pharmacy Benefit Managers (PBMs) relationships
- Co-payments and cost-reduction initiatives
- Managed Care Contracting: Pharmaceutical Manufacturers’ Perspective
- Managed Care Business Goals
- 6. Monitoring Performance
- 4.7.7.1.Drug Price Transparency in United States
- 4.7.7.2. Wal-Mart and $4 Generics
- 4.7.7.3. Average Wholesale Price and First Data Bank
- Current Pricing and Reimbursement Trends in Europe
- 5.1.1 EU Pricing Environment
- 5.1.2. Reimbursement Mechanisms
- 5.1.3. Pricing and Reimbursement impact on new product launch sequence
- 5.1.5. Pricing and Reimbursement Overview
- 5.2.2. Statutory Health Insurance Funds
- 5.2.3. Statutory Health Insurance Market
- 5.3.2. Regulatory Affairs in France
- 5.4.2. Pricing of New Products
- 5.4.3. Pricing Methods for Generic Products
- 5.6.2. Reference Pricing System
- 5.7.Tackling Parallel Trade
- Current Pricing and reimbursement Trends in Japan
- 6.2. Japanese Healthcare System
- Employee’s Health Insurance Plan
- National Public Health Insurance Plan
- 6.3. Reimbursement system
- 6.3. The R-Zone and regular price decreases
Prescribing Pharmacists: A Decision Maker Emerges
Chapter One: Executive Summary
- Markets – Pharmacists Impact
- The Prescribing Pharmacist
- Main Drivers For Increased Pharmacist Prescription Authority
- Issues and Trends Shaping the Industry
Chapter Two: Introduction
- Role of the US Pharmacist
- Role in Distributing Controlled Substances
- Variations in Prescribing Authority
- Earnings and Distribution by Employment Type
- Training and Certification
Chapter Three: Issues and Trends Shaping the Industry
- US Healthcare Expenditures
- Rising Healthcare Costs and Health Insurance Trends
- Units Sales and Revenues of Top Branded Drugs
- Population Growth and the Existing Need
- Reducing Errors in Hospitals
- Interactions and the Evolving Pharmaceutical Industry
- Prescribing Trends of Select Federal Programs
- State Comparison of Collaborative Practice
- Hospital Case Studies and Collaborative Drug Therapy Management
- Barriers to Collaborative Practice
Chapter Four: Pharmacist Impact on Pharmaceutical Markets
- Influencing Drug Dosage, Administration, or Other Therapy Aspects
- Therapeutic Areas Most Influenced
- chapter Five: The Emerging Prescribing Pharmacist
- Differing Views on Increasing Roles of the Pharmacist
- Physicians’ View on Increasing Involvement in Prescribing
- Pharmacists’ View on Increasing Involvement in Prescribing
- States Most Likely to Implement Independent Prescribing
APPENDIX: Nationwide Boards of Pharmacy
Table of Exhibits
Chapter One: Executive Summary
- Figure 1-1: Declining Drug Purchases Not Influenced By
- Pharmacist 2006-2012Table 1-1: Pharmacists Influence in Drug Selection and/or Therapy Aspect: 2006 and 2012
- Figure 1-2: Pharmacists Influence in Drug Selection and/or Drug Aspect, 2006 and 2012
Chapter Two: Introduction
- Table 2-1: Examples of Controlled Substances by Schedule
- Table 2-2: Number of Pharmacists in the Workforce 2004-2006
- Table 2-3: 2004 Median Annual Income Levels for U.S. Pharmacists
- Figure 2-1: 2004 Median Annual Income Levels for U.S. Pharmacists
- Table 2-4: 2005 Leading Employment Areas and Income Statistics for U.S. Pharmacists
- Table 2-5: 2006 Leading Employment Areas and Income Statistics for U.S. Pharmacists
- Figure 2-2: Number of Pharmacists (2005/2006) in Leading Employment Areas in the U.S.
- Figure 2-3: Mean Level of Income (2005/2006) for Leading Employment Areas in the U.S.
- Table 2-6: Pharmacist Concentrations for the Top Five States in 2006
- Figure 2-4: Pharmacist Concentrations for the Top Five States in 2006
- Table 2-7: Pharmacist Concentrations for the Top Five U.S. Metropolitan Areas in 2006
- Figure 2-5: Pharmacist Concentrations for the Top Five U.S. Metropolitan Areas in 2006
- Table 2-8: Number of Pharmacists Employed in all U.S. States, District of Columbia and U.S. Territories in 2006
- Figure 2-6: Top 20 States with the Most Pharmacists in the Workforce in 2006
- Table 2-9: Accredited Pharmacy Education Centers by State
Chapter Three: Issues and Trends Shaping the Industry
- Table 3-1: U.S. Prescription and Total Healthcare Expenditures 1995, 2000, and 2005
- Figure 3-1: U.S. Prescription and Total Healthcare Expenditures 1995, 2000, and 2005
- Table 3-2: Percent Insured in the U.S. by Income Level
- Figure 3-2: Percent Insured in the U.S. by Income Level
- Table 3-3: Health Insurance Trends in the United States 2003-2005
- Figure 3-3: Number Insured in the United States 2003-2005
- Table 3-4: Retail Pharmaceutical Sales in the U.S. 1995, 2000 and 2004
- Figure 3-4: Distribution of Retail Pharmaceutical Sales from 1995, 2000 and 2004
- Table 3-5: Top Ten Prescribed Branded Drugs by Estimated Unit Sales in the U.S.
- Table 3-5: Top Ten Prescribed Branded Drugs by Estimated Unit Sales in the U.S.
- Table 3-6: Top Ten Prescribed Branded Drugs and U.S. Revenues
- Figure 3-6: Top Ten Prescribed Branded Drugs and U.S. Revenues
- Table 3-7: Top Ten Prescribed Branded Drugs and Worldwide Revenues
- Figure 3-7: Top Ten Prescribed Branded Drugs and Worldwide Revenues
- Table 3-8: United States Population and Age Statistics
- Figure 3-8: United States Population and Age Statistics
- Table 3-9: Increase in the Oldest U.S. Population
- Figure 3-9: Increase in the Oldest U.S. Population
- Figure 3-10: Distribution of Fatal Prescribing Errors
- Table 3-10: Select 2007 Safety Alerts for Drugs and Therapeutic Biological Products
- Table 3-11: Drug Interaction Information
- Figure 3-11: Timeline of U.S. Pharmacy Collaboration
- Table 3-12: States That Allow Collaboration Agreements between Pharmacist and Physician
- Table 3-13: Pharmacists per Employment Category in Japan (2004)
Chapter Four: Pharmacist Impact on Pharmaceutical Markets
- Table 4-1: Pharmacists Influence in Drug Selection and/or Drug Therapy Aspect, 2006 and 2012
- Figure 4-1 : Pharmacists Influence in Drug Selection and/or Therapy Aspect, 2006 and 2012
- Table 4-2: Pharmacists Influence in the US Drug Market, Influencing Drug Choice, 2006
- Figure 4-2: Pharmacists Influence in the US Drug Market, Influencing Drug Choice, 2006
- Figure 4-3: Drug Markets Most Influenced by Pharmacists by Therapeutic Category, 2006
- Table 4-3: Pharmacists Influence in the US Drug Market, Influencing Drug Dosage, Administration, and Other Therapy Aspect, 2006
- Figure 4-3: Pharmacists Influence in the US Drug Market, Influencing Drug Dosage, Administration, and Other Therapy Aspect, 2006
chapter Five: The Emerging Prescribing Pharmacist
- Table 5-1: States Most Likely to Allow Prescription, Those to Follow, and States Not Likely to Allow Independent Prescribing
Growing “Out of Pocket” Healthcare Market (Spending on Surgeries, Pharmaceuticals and Other Healthcare Services), The
CHAPTER ONE: EXECUTIVE SUMMARY
- Out of Pocket Expenditures : Current Market
- The U.S. Healthcare Market
- The Need for Alternatives
- Inconsistent Quality of Care
- Consumers Who Pay Out of Pocket
- Persons with Chronic Medical Conditions
- Types Of Out Of Pocket Payments
- Flexible Spending Accounts
- Loans and Lines of Credit
- Non-Elective Procedures and Prescription Drugs
- Types of Expenses Financed
- Non-Elective Procedures and Prescription Drugs
- Trends In Out Of Pocket Spending
- Managed Care Cost Shifting
- Disease Management Programs
- Medicare Prescription Drug Benefit
- Medical Procedure Financing
- Types of Procedures Financed
CHAPTER TWO: HEALTH CARE PAYMENTS AND COVERAGE
- State-Licensed Health Insuring Organizations
- Commercial Health Insurers
- Blue Cross and Blue Shield Plans
- Health Maintenance Organizations
- Self-Funded Employee Health Benefit Plans
- The Uninsured And Underinsured
- Universal Federal Health Care Coverage
- State Health Care Coverage
- Current State Health Care Initiatives
- Federal Support of State Health Care Reform
CHAPTER THREE: OUT-OF-POCKET EXPENDITURES: THE CURRENT MARKET
- Overall Out-Of-Pocket Spending
- Flexible Spending Accounts
- Loans and Lines of Credit
- Non-Elective Procedures and Prescription Drugs
- Consumers Who Pay Out Of Pocket
- Persons with Chronic Conditions
CHAPTER FOUR: OUT-OF-POCKET EXPENDITURES: THE MARKET IN 2007-2011
- Out-of-Pocket Expenditure Growth Drivers
- Managed Care Cost-Shifting
- Out-of-Pocket Expenditure Growth Constraints
- Disease Management Programs
- Medicare Prescription Drug Benefit
- Private-Label OTC Medications
- Consumers Who Pay Out of Pocket
CHAPTER FIVE: SOURCES OF MEDICAL PROCEDURE FINANCING, 2006
- Types Of Procedures Financed
CHAPTER SIX: SOURCES OF MEDICAL PROCEDURE FINANCING, 2007-2011
- Increasing Share of Wallet
- New Credit Card Customer Segments
CHAPTER SEVEN: COMPANY PROFILES
- Capital One Healthcare Finance
- Springstone Patient Financing
- Target Clinical Medical Associates
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1:The U.S. Out of Pocket Healthcare Market, 2006-2011, Elective and Non-Elective Spending (in billions)
- Figure 1-2: U.S. Consumer Out-of-Pocket Health Care Expenditures by Service Required, 2006
- Figure 1-3: U.S. Healthcare Consumers Highly Likely to Pay Out of Pocket, 2006-2011 (millions)
- Figure 1-4: U.S. Healthcare Consumers Likely to Pay Out of Pocket, by Contributing Factor 2006 (Persons with Chronic Conditions, Medicaid, Disabled, Senior Citizens, Mentally Ill, Obese)
- Figure 1-5 : Average Share Paid Out of Pocket by U.S. Consumers, by Percentile of Total Health Care Spending and Type of Service, 2003
CHAPTER TWO: HEALTH CARE PAYMENTS AND COVERAGE
- Figure 2-1: National Health Expenditures (NHE) and NHE as a Percentage of GDP, 1980-2011
- Figure 2-2: Premium Increases vs. Increases in Workers’ Earnings and Inflation, 1989-2005
- Table 2-1:Selected U.S. Federal and State Health Care Oversight Bodies,2007
- Table 2-2:U.S. Health Care Coverage by State,2007
CHAPTER THREE: OUT-OF-POCKET EXPENDITURES: THE CURRENT MARKET
- Figure 3-4: Average Share Paid Out-of-Pocket by U.S. Consumers, by Percentile of Total Health Care Expenses, 2003
- Figure 3-5: Average Amount Paid Out-of-Pocket by U.S. Consumers, by Percentile of Total Health Care Expenses, 2003
- Figure 3-1: U.S. Consumer Out-of-Pocket Health Care Expenditures: Direct Payments, Co-Pays and Premiums, 2006
- Figure 3-2: U.S. Consumer Out-of-Pocket Health Care Expenditures by Payment Type, 2006
- Table 3-1: Credit Card Debt of Consumers with Medical Debt by HealthInsurance Status,2007
- Table 3-2: Credit Card Debt of Consumers with Medical Debt by Demographic Group, 2007
- Figure 3-3: Methods of Payment for Elective Procedures, 2006
- Figure 3-4: U.S. Consumer Out-of-Pocket Spending for Elective Procedures, Amount Financed vs. Paid with Cash or Check, 2003
- Figure 3-7:Average Share of U.S. Health Care Expenses Paid Out of Pocket, by Type of Service, 2003
- Figure 3-8: Average Share Paid Out of Pocket by U.S. Consumers, by Percentile of Total Health Care Spending and Type of Service, 2003
- Figure 3-9: Distribution of Out-of-Pocket Spending on Non-Elective Procedures for the Average Person, 2003 71
- Figure 3-10: Distribution of Out-of-Pocket Spending for the Average Person, by Spending Level and Type of Service, 2003
- Figure 3-11: Drug Cost Coverage by Payor Type (Public, Private, Cash), 1965, 1986, 2000, 2004
- Figure 3-12: Change in Out-of-Pocket Health Care Expenses for Medicaid Recipients, 1997 to 2002
- Figure 3-13: Out-of-Pocket Health Care Expenses for Disabled and Non-Disabled Medicaid Recipients, 1997 vs. 2002
- Table 3-3: Obesity in the U.S., 1980-2011
- Figure 3-14: Adults Under Age 65 with Chronic Conditions by Type of Insurance, 2003
CHAPTER FOUR: OUT-OF-POCKET EXPENDITURES: FORECASTED MARKET TO 2011
- Figure 4-1: Extent to Which Consumers Believe Cost-Shifting Will Result in Beneficial Outcomes, 2003
- Figure 4-2: Growth of U.S. Retail Clinics, 2001-2011
- Table 4-1: Selected Rx-to-OTC Switches in the United States, 1982-2007
- Table 4-2: Rx-to-OTC Switch Candidates in the U.S., 2007-2012
- Table 4-3: Cost Savings From Medical Tourism for Various Procedures, 2007
- Table 4-4:U.S. Consumer Out-of-Pocket Expenditures per Worker, 2001-2011
- Table 4-5: U.S. Consumer Out-of-Pocket Expenditures by Payment Type, 2001-2011
- Figure 4-3: Distribution of U.S. Consumer Out-of-Pocket Spending by Payment Type, 2001, 2006, 2011
- Table 4-6:U.S. Consumer Out-of-Pocket Expenditures by Payment Method, 2001-2011
- Figure 4-4: Distribution of U.S. Consumer Out-of-Pocket Spending by Payment Method, 2001, 2006, 2011
- Table 4-7: Amount of U.S. Consumer Out-of-Pocket Expenditures for Elective Procedures , 2001-2011 (in billion $)
- Figure 4-5: Share of U.S. Consumer Out-of-Pocket Spending for Elective Procedures Paid for Through Financing, 2006-2011
- Table 4-8: Amount of U.S. Consumer Out-of-Pocket Expenditures for Non-Elective Procedures , 2001-2011 (in billion $)
- Figure 4-6: Distribution of Out-of-Pocket Spending on Non-Elective Procedures for the Average Person, 2006 vs. 2011
- Figure 4-7: Share of U.S. Consumer Out-of-Pocket Spending for Non-Elective Procedures Paid for Through Financing, 2006-2011
- Table 4-9: Size of High-Risk Groups for High Out-of-Pocket Health Care Expenditures, 2001-2011 (in millions)
CHAPTER FIVE: SOURCES OF MEDICAL PROCEDURE FINANCING, 2006
- Figure 5-1:Distribution of Medical Procedure Financing Market, 2006
- Table 5-1:Cosmetic Surgical Procedures Offered in the U.S., 2007
- Table 5-2: Firtility Treatments in the U.S., 2007
- Table 5-3:Leading Weight Reduction Surgeries Offered in the U.S., 2007
- Table 5-4:Comparison of Selected Medical Financing Program Costs to Consumers, 2006
- Table 5-5:Selected Elective Procedures Covered by Leading Medical Financing Companies, 2007
- Figure 5-2:Leading Players’ Share of U.S. Elective Procedure Financing Market, 2006
- Table 5-6:Selected Non-Elective Procedures Covered by Leading Medical Financing Companies, 2007
- Figure 5-3:Leading Players’ Share of U.S. Elective Procedure Financing Market, 2006
CHAPTER SIX: SOURCES OF MEDICAL PROCEDURE FINANCING, 2007-2011
- Table 6-1: Consumer Out-of-Pocket Expenditures for Elective Procedures Paid Through Patient Financing Programs, 2001-2011 (in billion $)
- Table 6-2: Consumer Out-of-Pocket Expenditures for Non-Elective Procedures Paid Through Patient Financing Programs, 2001-2011 (in billion $)
- Figure 6-1: Consumer Out-of-Pocket Expenditures for Elective and Non-Elective Procedures Paid Through Patient Financing Programs, 2001-2011 (in billion $)
- Figure 6-2: Proportion of Consumer Out-of-Pocket Spending for Elective Procedures Paid Through Patient Financing Programs, 2006-2011
Retail Clinics, The Emerging Market for Convenience and In-Store Healthcare
CHAPTER ONE: Executive Summary
- The Emergence of Retail Clinics
- Establishing a Retail Clinic
- Clinical Chemistry and Immunoassays
- Types of Retail Outlets Offering Clinics
- Supermarkets and Food Stores
- Competition with Primary Care Providers
CHAPTER TWO: Introduction
- The U.S. Healthcare System Today
- The Need For Alternatives
- Inconsistent Quality of Care
- Advertising and Promotion
- Economic Pressures on Consumers
- Consumer Responsibility for Health Care
- Medical Community Response
- Reaction from Managed Care Organizations
- Ability to Meet Financial Expectations
- Establishing A Retail Clinic
CHAPTER THREE: Service Providers
- Convenience Clinic Sales Forecasts
- Competitive Positions of Key Players
CHAPTER FOUR: OPPORTUNITIES FOR DIAGNOSTIC AND PHARMACEUTICAL COMPNIES
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
- Clinical Chemistry and Immunoassays
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
CHAPTER FIVE: Retail Outlets
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
- Competitive Positions of Key Players
- Convenience Clinic Sales Forecasts
CHAPTER SIX: Total Market
- Opportunities for Suppliers
- Increased Revenue for Retailers
CHAPTER SEVEN: Issues and Trends
- Competition With Primary Care Providers
- Regulation of Convenience Clinics
CHAPTER EIGHT: Company Profiles
- SmartCare Family Medical Centers
- Target Clinic Medical Associates
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Estimated Number of U.S. Convenience Clinics, 2007 – 2011
- Figure-1-2: Locations of Retail Clinics, 2007
- Figure 1-3: Indirect Revenue to Drug Stores, Supermarkets, Mass Merchandising Outlets and Others with Retail Clinics
CHAPTER TWO: INTRODUCTION
- Figure 2-1: National Health Expenditures (NHE) and NHE as a Percent of GDP, 1980 – 2011
- Figure 2-2: Premium Increases vs. Increases in Workers Earnings and Prices, 1989 – 2005
- Figure 2-3: Unnecessary Deaths Resulting From Variations in Health Care Quality
- Figure 2-4: HEDIS Scores by Quality of Health Care Plan, 2006
- Figure 2-5: Change in Out of Pocket Health Care Expenses for Medicaid Recipients, 1997 – 2002
- Figure 2-6: Out of Pocket Health Care Expenses for Disabled and Non-Disabled Medicaid Recipients, 1997 vs. 2002
- Figure 2-7: Proportion of Adults Under Age 65 With Chronic Conditions, 2003
- Table 2-2: U.S. Health Care Coverage by State, 2007
- Table 2-3: Cost Savings From Medical Tourism, 2007
- Table 2-4: Estimated Number of U.S. Convenience Clinics, Expansion of U.S. Convenience Clinics by Major Chain (Aurora, QuickCare, Healthy Access, Minute Clinic, Quick Health, Solantis, Target Clinical, CheckUps, MedBasics, Now Medical Centers, RediClinic Others, Take Care Clinics, the Little Clinic) 2007 to 2011
- Figure 2-8: Expansion of U.S. Convenience Clinics by Major Chain (Aurora QuickCare, Healthy Access, Minute Clinic, Quick Health, Solantis, Target Clinical, CheckUps, MedBasics, Now Medical Centers, RediClinic Others, Take Care Clinics, the Little Clinic) 2007 to 2011
- Table 2-5: Characteristics of Retail Outlets, 2007 (Drug Stores, Food Stores, Mass Merchandizing Outlets)
- Table 2-6: Benefits and Drawbacks of Convenience Clinic Funding Approaches, 2007
- Table 3-1: The U.S. Market for Retail Clinic Services, 2001-2011
CHAPTER THREE: SERVICE PROVIDERS
- Figure 3-1: Growth of U.S. Retail Clinic Services, 2001-2011
- Table 3-2, Leading Service Providers’ Revenues and Market Share
- Figure 3-2: Market Shares of Leading Retail Clinic Service Provider, 2006
CHAPTER FOUR: OPPORTUNITIES FOR DIAGNOSTIC AND PHARMACEUTICAL COMPNIES
- Table 4-1: Sales to Retail Clinics by Supplier Segment, 2001-2011 (POC Tests, Clinical Chemistry & Immuno-assays, Vaccines)
- Figure 4-1: Growth of Retail Clinic Supplier Sales by Type of Supplies, 2001-2011 (POC Tests, Clinical Chemistry & Immuno-assays, Vaccines)
- Table 4-2: U.S. Professional POC Test Sales, 2001-2011
- Table 4-3: Leading POC Test Makers’ U.S. Revenues and Markert Share, 2006
- Table 4-4: U.S. Professional POC Test Sales to Retail Clinics, 2001-2011
- Table 4-5: U.S. Clinical Chemistry and Immunoassay Sales, 2001-2011
- Table 4-6: Leading Clinical Chemistry and Immunoassay Suppliers’ Revenues and Market Share, 2006
- Table 4-8: Diseases for which Vaccines are Available in the U.S., 2007
- Table 4-9: U.S. Market for Preventative Vaccines, 2001-2011
- Table 4-10: Leading Vaccine Manufacturers’ U.S. Revenues and Market Share, 2007
- Table 4-11: U.S. Vaccine Sales to Convenience Clinics, 2001-2011
CHAPTER FIVE: RETAIL OUTLETS
- Table 5-1: Number of Retail Clinics by Type of Retail Outlet (Drug Stores, Supermarkets, Mass Merchandising Outlets, Other), 2001-2011
- Figure 5-2: Proportion of Rents Collected From Retail Clinics by Type of Retail Outlet, 2001-2011 (Drug Stores, Supermarkets, Mass Merchandising Outlets, Others)
- Table 5-3: Indirect Income Generated by Retail Clinics by Type of Retail Outlet, 2001-2011, (Drug Stores, Supermarkets, Mass Merchandising Outlets, Others)
- Figure 5-3: Proportion of Indirect Income Generated by Retail Clinics by Type of Retail Outlet, 2001-2011 (Drug Stores, Supermarkets, Mass Merchandising Outlets, Others)
- Table 5-4: Selected Retail Outlet Relationships with Convenience Clinics, 2007
- Table 5-5: U.S. Drug Store Sales, 2001-2011
- Table 5-6 Leading U.S. Drug Stores’ Revenues and Market Share, 2006
- Table 5-7: U.S. Drug Store Direct Retail Clinic Revenues, 2001-2011 (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
- Table 5-8: U.S. Drug Store Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics, Patients/Clinic/Day, Incremental Sales per Patient, Total Indirect Revenue)
- Figure 5-4: Direct vs. Indirect Revenues to Drug Stores From Retail Clinics, 2001-2011
- Table 5-9: U.S. Food Store Sales, 2001-2011
- Table 5-10: Leading Food Stores Revenues and Market Share, 2006
- Table 5-11: U.S. Food Stores Direct Retail Clinic Revenues, 2001-2011 (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
- Table 5-12: U.S. Food Store Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics, Patients/Clinic/Day, Incremental Sales per Patient, Total Indirect Revenue)
- Figure 5-5: Direct vs. Indirect Revenues to Food Stores from Retail Clinics, 2001-2011
- Table 5-13: U.S. Mass Merchandiser Sales, 2001-2011
- Table 5-14: Leading Mass Merchandisers Revenues and Market Share, 2006
- Table 5-15: U.S. Mass Merchandiser Retail Clinic Revenues (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
- Table 5-16: U.S. Mass Merchandiser Indirect Retail Clinic Revenues, 2001-2011 (Number of Clinics, Patients/Clinic/Day, Incremental Sales per Patient, Total Indirect Revenue)
- Table 5-17: U.S. Other Retail Sales, 2001-2011
- Table 5-18: Leading Other Outlets Revenues and Market Share, 2006
- Table 5-19: US Other Outlets Direct Retail Clinics Revenues (No. of Stores, Sq. Ft Per Store, Cost Per Sq. Ft.)
- Table 5-20: U.S. Other Outlets Indirect Retail Clinic Revenues (Number of Clinics, Patients/Clinic/Day, Incremental Sales per Patient, Total Indirect Revenue)
CHAPTER SIX: MARKET SUMMARY
- Table 6-1: Retail Clinic Service Revenues, 2001-2011
- Table 6-2: Sales to Retail Clinics by Suppliers 2001-2011
- Figure 6-1: Revenues from Retail Clinics (Direct Rents/Indirect Revenues)
CHAPTER SEVEN: ISSUES AND TRENDS
- Table 7-1: Selected U.S. Federal and State Health Care Oversight Bodies, 2007
Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies, The
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER TWO: RX-TO-OTC PRODUCT AND MARKET ANALYSIS
- Osteoporosis and Hormone Replacement Therapy
- Nicotrol Inhalation and Nasal Spray
CHAPTER THREE: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC SWITCH INDUSTRY
- Consumers and Rx-to-OTC Switches
- Direct-to-Consumer (DTC) Advertising
- FDA Again Considering Third Class of Medicines
- Insurance Reimbursement Issues
- OTC Switch Criteria and FDA Involvement
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1: Major Markets for Rx to OTC 2008 and 2010
- Figure 2: Number of New Rx-to-OTC Switches per Year 1976-2007
CHAPTER TWO: RX-TO-OTC PRODUCT AND MARKET ANALYSIS
- Figure 3: Revenue, Major Rx to OTC Categories, 2008
- Table 1: Potential Rx-to-OTC Switches, 2008-2013
- Table 2: Rx-to-OTC Market Analysis: Allergy and Cold Treatments
- Table 3: Rx-to-OTC Market Analysis: Antilipidemic Agents
- Table 4: Rx-to-OTC Market Analysis: Fungal Infection Treatments
- Table 5: Rx-to-OTC Market Analysis: Gastrointestinal Treatments
- Table 6: Rx-to-OTC Market Analysis: Hair Loss Treatments
- Table 7: Rx-to-OTC Market Analysis: Migraine Therapies
- Table 8: Rx-to-OTC Market Analysis: NSAIDs
- Table 9: Rx-to-OTC Market Analysis: Oral Contraceptives
- Table 10: Rx-to-OTC Market Analysis: Sleep Agents
- Table 11: Rx-to-OTC Market Analysis: Smoking Cessation
CHAPTER THREE: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC SWITCH INDUSTRY
- Table 12 Leading Rx-to-OTC Switches 1994-2007
- Figure 1: Number of New Rx-to-OTC Switches per Year 1976-2007
- Table 13: Health Insurance Trends in the United States 2003-2006
